Lanadelumab

Generic name
Lanadelumab
Brand name
ATC Code
B06AC05
Compare …

Lanadelumab

Dosages
Side effects in children
Warnings & precautions in children
Contra-indications in children

Interactions
PK
Renal impairment
References

Pharmacokinetics in children

After subcutaneous administration of 150 mg every 4 weeks (2 to 6 years) and 150 mg every 2 weeks (6 to 12 years), overall exposure (i.e. Cavg,ss) to lanadelumab was similar in adult and adolescent (12 to 18 years) patients.

dose recommendation of formulary compared to licensed use (on-label versus off-label)

No information is present at this moment.

Available formulations

No information is present at this moment.

Dosages

Routine prevention of angio-oedema episodes
  • Subcutaneous
    • 2 years up to 18 years and 10 up to 20 kg
      • 150 mg/dose every 4 weeks.

      • In case of insufficient effect, the dose may be increased to 150 mg every 3 weeks. 

    • 2 years up to 18 years and 20 up to 40 kg
      • 150 mg/dose every 2 weeks.

      • In case of stably attack-free disease, the dose may be decreased to 150 mg every 4 weeks. 

    • 2 years up to 18 years and ≥ 40 kg
      • 300 mg/dose every 2 weeks.

      • In case of stably attack-free disease, the dose may be decreased to 300 mg every 4 weeks. 

Renal impaiment in children > 3 months

GFR ≥10 ml/min/1.73m2: Dose adjustment not required.

GFR <10 ml/min/1.73m2: A general recommendation on dose adjustment cannot be provided.

The complete list of all undesirable drug reactions can be found in the national Summary of Product Characteristics (SmPC) – click here

Side effects in children

The side effect profile in children does not differ from that in adults.

The complete list of all contra-indications can be found in the national Summary of Product Characteristics (SmPC) – click here

Contra-indications

No information available on specific contra indications in children.

The complete list of all warnings and precautions can be found in the national Summary of Product Characteristics (SmPC) – click here

Warnings & precautions

No information available on specific warnings and precautions in children.

Interactions

The complete list of all interactions can be found in the national Summary of Product Characteristics (SmPC) – click here

OVERIGE HEMATOLOGISCHE MIDDELEN

This pages provides a list of drugs from the same ATC class for comparison. This does not necessarily mean that these drugs are interchangeable.

Enzymes
B06AA03
Drugs used in hereditary angioedema
B06AC04
B06AC02

References

  1. Takeda Pharmaceuticals International AG Ireland Branch , SmPC Takhzyro (EU EU/1/18/1340/001) Rev 12; 22-11-2023 , www.ema.europa.eu
  2. Takeda Pharmaceuticals International AG Ireland Branch, SmPC Takhzyro (EU EU/1/18/1340/001) Rev 12; 22-11-2023, www.ema.europa.eu

Changes

Therapeutic Drug Monitoring


Overdose